The Measurement Performance of the EQ-5D-5L Versus EQ-5D-3L in Patients with Hidradenitis Suppurativa

Author(s)

Bató A1, Brodszky V2, Gergely HL3, Gáspár K4, Wikonkál N3, Kinyó Á5, Beretzky Z6, Szegedi A4, Remenyik É7, Kiss NF3, Sárdy M3, Bánvölgyi A3, Rencz F8
1Corvinus University of Budapest, Budapest, Hungary, 2Corvinus University of Budapest, Department of Health Economics, Budapest, PE, Hungary, 3Semmelweis University, Faculty of Medicine, Department of Dermatology, Venereology and Dermatooncology, Budapest, Hungary, 4University of Debrecen, Faculty of Medicine, Departments of Dermatology & Department of Dermatological Allergology, Debrecen, Hungary, 5University of Pécs Medical School, Department of Dermatology, Venereology and Oncodermatology, Pécs, Hungary, 6Corvinus University of Budapest, Doctoral School of Business and Management & Department of Health Economics, Budapest, Hungary, 7University of Debrecen, Faculty of Medicine, Departments of Dermatology, Debrecen, Hungary, 8Hungarian Academy of Sciences, Premium Postdoctoral Research Programme & Corvinus University of Budapest, Department of Health Economics, Budapest, Hungary

OBJECTIVES: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that affects up to 1% of the population in Europe. The EQ-5D-3L is the most commonly used generic instrument for measuring health-related quality of life among HS patients. Little is known about the performance of the newer, five-level version of the questionnaire (EQ-5D-5L) in this patient population. This study aims to compare the measurement properties of the two adult versions of EQ-5D (3L and 5L) in patients with HS.

METHODS: Between September 2017 and October 2019, we carried out a cross-sectional survey at three academic dermatology clinics in Hungary. We recruited 200 consecutive patients with HS to participate in the study. Patients completed the 3L, 5L, Dermatology Life Quality Index (DLQI) and Skindex-16.

RESULTS: Overall 62% of the patients were male, and the mean age was 37 years. More than twice as many different health state profiles occurred in the 5L compared to the 3L (101 vs 43). Ceiling effects slightly decreased from 16.0% (3L) to 14.6% (5L). A good agreement was established between the 3L and 5L with an of ICC 0.872 (95% CI 0.830-0.903; p<0.001) that was confirmed by using a Bland-Altman plot. The 5L improved the absolute discriminatory power (Shannon’s index) of the questionnaire in all dimensions. The 5L correlated stronger with both the DLQI and Skindex-16 in 3/5 dimensions, and was able to discriminate better between known groups of patients based on education level, smoking status, body mass index, disease severity and treatments.

CONCLUSIONS: In patients with HS, the 5L outperformed the 3L in feasibility, ceiling effects, discriminatory power, convergent and know-groups validity. We recommend using the 5L version of the EQ-5D in HS patients across various settings, including clinical care, research and economic evaluations.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PSY30

Topic

Clinical Outcomes, Patient-Centered Research

Topic Subcategory

Clinical Outcomes Assessment, Instrument Development, Validation, & Translation, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×